{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:34Z","timestamp":1792521934270,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T15:56:41Z","timestamp":1726329401000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Innovation in Dermatomyositis"],"prefix":"10.1016","volume":"43","author":[{"given":"Kimberly B.","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina S.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2024.08.008_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.det.2024.08.008_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2024.08.008_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2024.08.008_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2230.2009.03216.x","article-title":"Defining cancer risk in dermatomyositis. Part I","volume":"34","author":"Madan","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.008_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2230.2009.03227.x","article-title":"Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology","volume":"34","author":"Madan","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.008_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol Clin"},{"issue":"6","key":"10.1016\/j.det.2024.08.008_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2007.08.024","article-title":"Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center","volume":"57","author":"Klein","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.008_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2020.02.061","article-title":"Malignancy in dermatomyositis: a retrospective study of 201 patients seen at the University of Pennsylvania","volume":"83","author":"Bowerman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.08.008_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.det.2024.08.008_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.det.2024.08.008_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis autoantibodies: how can we maximize utility?","volume":"9","author":"Hodgkinson","year":"2021","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.det.2024.08.008_bib12","doi-asserted-by":"crossref","first-page":"e150201","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.det.2024.08.008_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2024.08.008_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Moghadam-Kia","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.det.2024.08.008_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.det.2024.08.008_bib16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.det.2024.08.008_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.008_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.det.2024.08.008_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"issue":"1","key":"10.1016\/j.det.2024.08.008_bib20","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/j.det.2024.08.008_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"issue":"11","key":"10.1016\/j.det.2024.08.008_bib22","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.det.2024.08.008_bib23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.008_bib24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.08.008_bib25","unstructured":"Priovant Therapeutics, Incorporated. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis. ClinicalTrials.gov identifier: PVT-2201-301."},{"key":"10.1016\/j.det.2024.08.008_bib26","unstructured":"Pfizer. A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]. ClinicalTrials.gov identifier: C0251006."},{"issue":"1","key":"10.1016\/j.det.2024.08.008_bib27","doi-asserted-by":"crossref","first-page":"e23677","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\"ProDERM Study\")","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.det.2024.08.008_bib28","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.eclinm.2023.102234","article-title":"Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study","volume":"64","author":"Werth","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.det.2024.08.008_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.det.2024.08.008_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2014-205800","article-title":"Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study","volume":"75","author":"Carruthers","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.det.2024.08.008_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2023.1105","article-title":"Intravenous immunoglobulin and dermatomyositis-associated venous thromboembolism","volume":"159","author":"Rotrosen","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.008_bib32","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.008_bib33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.08.008_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.det.2024.08.008_bib35","unstructured":"Vleugels R.A., The efficacy, safety, and tolerability of PF-06823859, an interferon-\u00df specific monoclonal antibody, in adult patients with skin-predominant dermatomyositis: results of a phase 2, double-blind, randomized placebo controlled study [abstract]. In: Late breaking Research Symposium at the American Academy of Dermatology; 2023; New Orleans, LA, March 17-21 2023."},{"issue":"3","key":"10.1016\/j.det.2024.08.008_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2024.08.008_bib37","doi-asserted-by":"crossref","first-page":"1046687","DOI":"10.3389\/fphar.2022.1046687","article-title":"Targeting type I interferons in systemic lupus erythematous","volume":"13","author":"Bruera","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.det.2024.08.008_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:03:06Z","timestamp":1755694986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000809"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation in Dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}